SE7512192L - Cancerantigen, cancerterapi och cancerdiagnostikum - Google Patents

Cancerantigen, cancerterapi och cancerdiagnostikum

Info

Publication number
SE7512192L
SE7512192L SE7512192A SE7512192A SE7512192L SE 7512192 L SE7512192 L SE 7512192L SE 7512192 A SE7512192 A SE 7512192A SE 7512192 A SE7512192 A SE 7512192A SE 7512192 L SE7512192 L SE 7512192L
Authority
SE
Sweden
Prior art keywords
cancer
iac
antibodies
therapy
antiges
Prior art date
Application number
SE7512192A
Other languages
English (en)
Swedish (sv)
Inventor
Kurt Baekgaard Osther
Original Assignee
Kurt Baekgaard Osther
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK564774A external-priority patent/DK564774A/da
Priority claimed from DK70875A external-priority patent/DK70875A/da
Priority claimed from DK157475A external-priority patent/DK157475A/da
Application filed by Kurt Baekgaard Osther filed Critical Kurt Baekgaard Osther
Publication of SE7512192L publication Critical patent/SE7512192L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE7512192A 1974-10-30 1975-10-30 Cancerantigen, cancerterapi och cancerdiagnostikum SE7512192L (sv)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK564774A DK564774A (da) 1974-10-30 1974-10-30 Opfindelsen angar imunglobuliner rettet mod maskerende proteiner pa humane cancercellemembraner
DK70875A DK70875A (da) 1975-02-25 1975-02-25 Demaskering af cancer cellemembraner, ved hjelp af specifikke antistoffer. immunoglobuliner rettet mod maskerende proteiner pa humane cancercelle membraner
DK157475A DK157475A (da) 1975-04-11 1975-04-11 Fremgangsmade til fremstilling af et cancerassocieret protein
DK386475 1975-08-27
DK450375 1975-10-06

Publications (1)

Publication Number Publication Date
SE7512192L true SE7512192L (sv) 1976-06-16

Family

ID=27512806

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7512192A SE7512192L (sv) 1974-10-30 1975-10-30 Cancerantigen, cancerterapi och cancerdiagnostikum

Country Status (14)

Country Link
US (1) US4132769A (no)
JP (1) JPS5191322A (no)
AU (1) AU518663B2 (no)
BE (1) BE835020A (no)
CA (1) CA1083037A (no)
CH (1) CH635242A5 (no)
DE (1) DE2548636A1 (no)
FI (1) FI56117C (no)
FR (1) FR2289205A1 (no)
GB (1) GB1531762A (no)
NL (1) NL7512678A (no)
NO (1) NO753638L (no)
NZ (1) NZ179095A (no)
SE (1) SE7512192L (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598811A (en) * 1977-01-12 1981-09-23 Hoffmann La Roche Carcinoma-associated antigens
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
JPS548714A (en) * 1977-06-16 1979-01-23 Saikin Kagaku Kenkiyuushiyo Kk Production of specific antiserum
US4620972A (en) * 1978-02-27 1986-11-04 Lakatos George C Method of inhibiting the growth of malignant tumor cells
US6410697B1 (en) 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
JPS5729949A (en) * 1980-07-30 1982-02-18 Nippon Koutai Kenkyusho:Kk Determination of sugar branch related to cancer and diagnostic technique of cancer
US4447545A (en) * 1980-11-03 1984-05-08 New England Deaconess Hospital Bladder cancer detection
US4525459A (en) * 1982-01-27 1985-06-25 University Of Miami New purified glycoproteins and use in diagnosing infectious mononucleosis
US4489167A (en) * 1981-06-02 1984-12-18 Baxter Travenol Laboratories, Inc. Methods and compositions for cancer detection
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
GB2121417A (en) * 1982-02-22 1983-12-21 Carlton Med Prod Antigens and antibodies useful in the detection of cancer
AU569467B2 (en) * 1982-04-07 1988-02-04 Baylor College Of Medicine Immunoglobulin based cancer treating pharmaceutical compositions
IE820942L (en) * 1982-04-21 1983-10-21 Bartos Patent Dev Holding Determining in-viro effectiveness of cytostatic agents
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
ZA84617B (en) * 1983-02-14 1984-09-26 Arup Sen Synthetic polypeptides from viryl oncogenes
JPH0639385B2 (ja) * 1983-04-18 1994-05-25 精次 高山 新規免疫抗癌剤及びその製法
US4524026A (en) * 1983-08-29 1985-06-18 Yoshio Sakagami Novel proteinous cancer-cell proliferation inhibitory factors
US5665216A (en) * 1986-10-21 1997-09-09 Northeastern University Capillary column for high performance electrophoretic separation and detection of SDS proteins and system and using the same
US4997537A (en) * 1986-10-21 1991-03-05 Northeastern University High performance microcapillary gel electrophoresis
US5171666A (en) * 1988-04-22 1992-12-15 Eli Lilly And Company Monoclonal antibodies reactive with a cell-surface gylcoprotein expressed on human carcinomas
US5008183A (en) * 1988-05-10 1991-04-16 Bio-Research Laboratories, Inc. Assay system for detecting antibody and a method of producing non-human immune antibody
US5286852A (en) * 1988-07-06 1994-02-15 Verigen, Inc. Antibodies specific towards HIV-1 gp 48
US5658569A (en) * 1988-07-06 1997-08-19 Verigen, Inc. Anti-HIV-1 neutralizing antibodies
US5529776A (en) * 1988-07-06 1996-06-25 Verigen Inc. Anti-HIV-1 neutralizing antibodies
US5179198A (en) * 1988-07-11 1993-01-12 Hidechika Okada Glycoprotein and gene coding therefor
US5179008A (en) * 1989-02-09 1993-01-12 Wisconsin Alumni Research Foundation Hybridoma and monoclonal antibody to FHAP
US5001052A (en) * 1989-02-09 1991-03-19 Wisconsin Alumni Research Foundation Immunoassay for FHAP and antibody useful therewith
WO1994003470A1 (en) * 1992-08-10 1994-02-17 Davies Richard J Method and apparatus for screening and diagnosing for cancers
US6218171B1 (en) * 1998-06-18 2001-04-17 Battelle Memorial Institute Microbial methods of reducing technetium
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
KR100906102B1 (ko) 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US6627607B2 (en) * 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
EP2272946B9 (en) 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minicell compositions and methods
US8494781B2 (en) * 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US20050059101A1 (en) * 2003-09-10 2005-03-17 Gordon Ringold Bivalent targeting of cell surfaces
BRPI0417797A (pt) * 2003-12-18 2007-03-20 Owen Holding Ltd soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos
US9254315B2 (en) * 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US8135595B2 (en) * 2004-05-14 2012-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Computer systems and methods for providing health care
AU2007319669A1 (en) * 2006-05-30 2008-05-22 Elenore S. Bogoch Replikin peptides and uses thereof
AU2008266702A1 (en) * 2007-05-30 2008-12-24 Elenore S. Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
US20120179389A1 (en) * 2009-08-20 2012-07-12 Spectrosense Ltd. Gas Chromatographic Analysis Method and System
EP2734226A2 (en) 2011-07-20 2014-05-28 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
WO2016081889A1 (en) 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
CA3013522A1 (en) * 2016-02-05 2017-08-10 Dana Genetic A/S Method for diagnosing and treating cancer using antibodies that bind to c1 inactivator, c reactive protein and/or complement component c4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2165370A (en) * 1936-10-06 1939-07-11 Lakeland Foundation Carcinoma antigen
US3663684A (en) * 1970-06-01 1972-05-16 Hoffmann La Roche Carcinoembryonic antigen and diagnostic method using radioactive iodine
US3697638A (en) * 1970-06-01 1972-10-10 Hoffmann La Roche Antigens
US3867363A (en) * 1970-06-01 1975-02-18 Hans John Hansen Carcinoembryonic antigens
US3956258A (en) * 1972-05-12 1976-05-11 Hoffmann-La Roche Inc. Carcinoembryonic antigens
IN138903B (no) * 1972-07-10 1976-04-10 K Bjorklund
US3960827A (en) * 1972-07-10 1976-06-01 Bjoerklund K B Cancer associated polypeptide antigen, process for its preparation, process for preparing antibodies, process of cancer diagnosis and composition useful as an immunizing agent
ZA723264B (en) * 1972-10-13 1974-08-28 H Van Til Improvements in toys
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies

Also Published As

Publication number Publication date
DE2548636A1 (de) 1976-05-13
FI56117C (fi) 1979-12-10
NO753638L (no) 1976-07-16
CA1083037A (en) 1980-08-05
NZ179095A (en) 1978-11-13
NL7512678A (nl) 1976-05-04
FI753025A (no) 1976-05-01
AU8609475A (en) 1977-05-05
FR2289205B1 (no) 1981-11-13
BE835020A (fr) 1976-04-29
GB1531762A (en) 1978-11-08
FI56117B (fi) 1979-08-31
JPS5191322A (no) 1976-08-10
CH635242A5 (fr) 1983-03-31
US4132769A (en) 1979-01-02
FR2289205A1 (fr) 1976-05-28
AU518663B2 (en) 1981-10-15

Similar Documents

Publication Publication Date Title
SE7512192L (sv) Cancerantigen, cancerterapi och cancerdiagnostikum
SE7709113L (sv) Endoskop, serskilt rektoskop
IT995014B (it) Antigene carcinoembrionale per uso diagnostico
DK69890A (da) Monoklonale antistoffer, der er reaktive med cachetin
SE7711118L (sv) Med ihaliga fibrer forsedd anordning, serskilt avsedd for anvendning som konstgjord njure samt forfarande for framstellning av denna anordning
NL169956C (nl) Inrichting voor diagnostisch onderzoek met ultrageluidsbundels.
NL7605187A (nl) Bloeddrukmeter.
SE7611307L (sv) Anordning for blodundersokning
SE7614395L (sv) Sett och anordning for ultraljudsundersokning
SE380901B (sv) Automatisk vetskeanalysapparat, serskilt blodanalysapparat
NL7811382A (nl) Ventiel met dubbele zitting met lekcontrole.
NO147401C (no) Klebende tampong for hudtesting.
FR2350106A1 (fr) Lame de verification de sterilite biologique echelonnee
NL7704629A (nl) Sondelichaam met sonde-omhulling.
IT7827180A0 (it) Procedimento e reagente per la determinazione della alfa-amilasi.
ATA39576A (de) Tragbarer mediziindiagnostischer apparat
SE396691B (sv) Forfarande och anordning for icke-invasiv biofysisk diagnos
NO153910C (no) Direkte agglutineringsproeve for paavisning av antigener i kroppsvaesker.
NL7800807A (nl) Ultrasoon detectie+instrument.
NL7803602A (nl) Ultrasone testinrichting.
CH547627A (de) Applikator fuer medizinische untersuchungen.
NL179451B (nl) Tomografische inrichting.
NL7609892A (nl) Werkwijze en inrichting voor lichaamsonder- zoek.
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
SU562615A1 (ru) Рыбозаградительное устройство водозаборного сооружени

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 7512192-1